Business Description
Strata Skin Sciences Inc
NAICS : 339112
SIC : 3841
ISIN : US86272A2069
Total Employee Number:
114Description
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | 0.1 | |||||
Debt-to-Equity | 5.59 | |||||
Debt-to-EBITDA | -346.13 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -11.59 | |||||
Beneish M-Score | -3.37 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -14.1 | |||||
3-Year EBITDA Growth Rate | -51.1 | |||||
3-Year EPS without NRI Growth Rate | 1.2 | |||||
3-Year FCF Growth Rate | 12 | |||||
3-Year Book Growth Rate | -57.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.58 | |||||
Quick Ratio | 0.48 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 79.02 | |||||
Days Sales Outstanding | 52.1 | |||||
Days Payable | 78.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.3 | |||||
Shareholder Yield % | -170985 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.83 | |||||
Operating Margin % | -19.74 | |||||
Net Margin % | -21.13 | |||||
EBITDA Margin % | -0.15 | |||||
FCF Margin % | -13.87 | |||||
OCF Margin % | -9.15 | |||||
ROE % | -266.41 | |||||
ROA % | -20.12 | |||||
ROIC % | -23.49 | |||||
3-Year ROIIC % | 14.82 | |||||
ROC (Joel Greenblatt) % | -43.31 | |||||
ROCE % | -29.37 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.85 | |||||
EV-to-EBITDA | -177.83 | |||||
EV-to-Revenue | 0.27 | |||||
EV-to-Forward-Revenue | 1.01 | |||||
EV-to-FCF | -1.96 | |||||
Price-to-GF-Value | 0.06 | |||||
Earnings Yield (Greenblatt) % | -54.05 | |||||
FCF Yield % | -213100 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Strata Skin Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 26.784 | ||
| EPS (TTM) (€) | -1.363 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -1.03 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.76 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.76 - 3.76 | ||
| Shares Outstanding (Mil) | 5.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Strata Skin Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Strata Skin Sciences Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-10 09:00 | In 153 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 126 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 16:30 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 33 days | ||
| Annual report for 2025 | 2026-03-26 | 3.76 (+0.00%) | ||
| General meeting for 2025 | 2025-12-10 09:00 | 3.76 (+0.00%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-13 16:30 | 3.76 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 3.76 (+0.00%) | ||
| H.C. Wainwright 27(th) Annual Global Investment Conference | 2025-09-05 07:00 | 3.76 (+0.00%) |
Show
Entries
Strata Skin Sciences Inc Frequently Asked Questions
What is Strata Skin Sciences Inc(FRA:E2O)'s stock price today?
The current price of FRA:E2O is €3.76. The 52 week high of FRA:E2O is €3.76 and 52 week low is €3.76.
When is next earnings date of Strata Skin Sciences Inc(FRA:E2O)?
The next earnings date of Strata Skin Sciences Inc(FRA:E2O) is 2026-08-13 Est..
Does Strata Skin Sciences Inc(FRA:E2O) pay dividends? If so, how much?
Strata Skin Sciences Inc(FRA:E2O) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating STRATA Skin Sciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors | 2018-11-07 |
Articles on Strata Skin Sciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers